Institut du Cancer de Montpellier - Val d'Aurelle

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

2 drugs in development

Approved1

Phase 21

Preclinical1

By Therapeutic Area

top 4

Oncology

120%

Cardiovascular

120%

Neurology

120%

Infectious Disease

120%

R&D Momentum

49/100

Pipeline Velocity

11/100

Trial Completion Rate

82/100

Pipeline Concentration

20/100

Pipeline Freshness

28/100

Strategic Signals

↗Active in Oncology but thin pipeline — potential licensing opportunity

Activity

Key Events

Jun 24, 2026TrialObservational Study of Intra-operative Partial Irradiation of Invasive Ductal Breast Carcinomas With a Good Prognosis

Jun 24, 2026TrialRandomized Phase II Study Evaluating Late Toxicity Following Intensity-Modulated Radiotherapy and Two Image-Guided Strategies With Corresponding Treatment Margins. (RCMIGI)

Jun 24, 2026TrialPain Monitoring After Breast Biopsy: Benefit of E-health

Oct 1, 2025TrialAnalysis of Circulating Tumor Markers in Blood - ALCINA 5

Sep 1, 2025TrialDevelopment of Clinical and Biological Database on Bronchial Cancer

Dec 19, 2023TrialPrecision Imaging for Early Detection and Targeted Treatment Monitoring in Pancreatic Cancer

Dec 19, 2023TrialUnravelling Tumour Biology In Ovarian Cancer With Precision Imaging

Dec 23, 2021TrialA Clinico-biological Database in Cachexia in Patients With Colon Cancer

4 more events

Nov 26, 2021TrialStudy Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma

Oct 18, 2021TrialAssessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET

Feb 18, 2021TrialLiquid Biopsies and IMAging for Improved Cancer Care

Dec 4, 2020TrialA Comparative Study of Pravastatin vs Placebo as Primary Prevention of Severe Subcutaneous Breast Fibrosis in Hyper-radiosensitive Identified Patients With Breast Cancer

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)

Institut du Cancer de Montpellier - Val d'Aurelle

Pipeline Snapshot

Key Events

Company Info

Drug Pipeline

Cardiovascular

Infectious Disease

Neurology

Oncology

Unknown / Other

Cardiovascular

Infectious Disease

Neurology

Oncology

Unknown / Other